BC World Pharm

Plant in Yeoju, Gyeonggi-do, which added freeze-drying capability in 2011 and completed its global facility in 2016; it runs tablet, capsule, powder and liquid injection, ampoule and freeze-dried injection lines to PIC/S, EU-GMP and cGMP standards.

Contract development and manufacturing from development through production and commercialization; as of March 2025 it produced more than 318 products for more than 93 companies.

Runs its pipeline in four streams: long-acting injectables, orally disintegrating tablets, incrementally modified drugs and generics.

Amlodipine besylate orally disintegrating tablet (5 and 10 mg) for hypertension that dissolves in the mouth without water and uses taste-masking technology; the company's third ODT product.

Injection that prevents nausea and vomiting from chemotherapy, radiotherapy and surgery.

Received Ministry of Food and Drug Safety approval for the hypertension treatment Ambaroodi 5 mg and 10 mg (amlodipine besylate orally disintegrating tablets).

Received approval for Bonova, a P-CAB gastric acid suppressant containing vonoprazan fumarate, for gastric ulcer, treatment and maintenance of erosive reflux disease, and prevention of ulcer recurrence during NSAID use; the launch date has not been set.

Launched Stapino, a combination tablet for dyslipidemia.